Patents by Inventor Natalie Roy
Natalie Roy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120094922Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP.Type: ApplicationFiled: November 2, 2011Publication date: April 19, 2012Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 8071327Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: GrantFiled: August 2, 2010Date of Patent: December 6, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Publication number: 20110059465Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: ApplicationFiled: August 2, 2010Publication date: March 10, 2011Applicant: Sanford-Bumham Medical Research InstituteInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 7794961Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: GrantFiled: January 9, 2007Date of Patent: September 14, 2010Assignee: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 7235372Abstract: The invention provides a novel NAIP nucleic and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.Type: GrantFiled: January 10, 2006Date of Patent: June 26, 2007Assignee: University of OttawaInventors: Robert G. Korneluk, Alexander E. MacKenzie, Natalie Roy, George Robertson, Katsu Tamai
-
Publication number: 20070128677Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: ApplicationFiled: January 9, 2007Publication date: June 7, 2007Applicant: The Burnham InstituteInventors: John Reed, Quinn Deveraux, Guy Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 7192728Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: GrantFiled: March 5, 2001Date of Patent: March 20, 2007Assignee: The Burnham InstituteInventors: John C Reed, Quinn Deveraux, Guy S Salvesen, Ryosuke Takahashi, Natalie Roy
-
Publication number: 20060172348Abstract: The invention provides a novel NAIP nucleic and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.Type: ApplicationFiled: January 10, 2006Publication date: August 3, 2006Applicant: University of OttawaInventors: Robert Korneluk, Alexander MacKenzie, Natalie Roy, George Robertson, Katsu Tamai
-
Patent number: 6994957Abstract: The invention provides NAIP nucleic acid and sequences. Also provided are anti-NAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.Type: GrantFiled: January 17, 1997Date of Patent: February 7, 2006Assignee: University of OttawaInventors: Robert G. Korneluk, Alexander E. MacKenzie, Natalie Roy, George Robertson
-
Publication number: 20020137028Abstract: The invention provides NAIP nucleic acid and sequences. Also provided are antiNAIP antibodies and methods for modulating apoptosis and detecting compounds which modulate apoptosis.Type: ApplicationFiled: September 12, 1997Publication date: September 26, 2002Inventors: ROBERT G KORNELUK, ALEXANDER E. MACKENZIE, NATALIE ROY, GEORGE ROBERTSON, KATSU TAMAI
-
Patent number: 6429011Abstract: The gene for autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.Type: GrantFiled: January 28, 2000Date of Patent: August 6, 2002Assignees: University of Ottawa, Research Development Corporation of JapanInventors: Alex E. MacKenzie, Robert G. Korneluk, Natalie Roy, Mani S. Mahadevan, Michael McLean, Joh-E Ikeda
-
Publication number: 20020009757Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: ApplicationFiled: March 5, 2001Publication date: January 24, 2002Applicant: THE BURNHAM INSTITUTEInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Publication number: 20010018195Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: ApplicationFiled: March 5, 2001Publication date: August 30, 2001Applicant: THE BURNHAM INSTITUTEInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 6228603Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.Type: GrantFiled: April 10, 1998Date of Patent: May 8, 2001Assignee: The Burnham InstituteInventors: John C. Reed, Quinn Deveraux, Guy S. Salvesen, Ryosuke Takahashi, Natalie Roy
-
Patent number: 6020127Abstract: The gene for the autosomal recessive neurodegenerative disorder Spinal Muscular Atrophy has been mapped to a region of chromosome 5. The gene encodes a protein having homology with apoptosis inhibitor proteins of viruses so that the encoded protein has been labelled as a neuronal apoptosis inhibitor protein (NAIP). A deletion in the (NAIP) domain was identified in persons with Type I, II and III Spinal Muscular Atrophy (SMA) and not in the normal non-SMA population.Type: GrantFiled: June 20, 1997Date of Patent: February 1, 2000Assignees: The University of Ottawa, Research Development Corp. of JapanInventors: Alex E. MacKenzie, Robert G. Korneluk, Natalie Roy, Mani S. Mahadevan, Michael McLean, Joh-E Ikeda